TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03324295

Intervention type: DIAGNOSTIC_TEST
Intervention: cortical cataract
Description: Blood urea

Intervention type: DIAGNOSTIC_TEST
Intervention: cortical cataract
Description: Blood urea

Intervention type: DIAGNOSTIC_TEST
Intervention: cortical cataract
Description: Blood urea
Study: NCT04590105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone App SB Colonoscopy Prep
Description: We created a smartphone app that informs patients about their colonoscopy procedure, alerts them when to take their medications throughout the hours-long colonoscopy prep process and tells them when to arrive to the endoscopy suite.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Written Instruction
Description: Written Instruction
Study: NCT00953966

Intervention type: OTHER
Group type: OTHER
Intervention: Genetically modified potatoes
Description: Starch from genetically modified potatoes

Intervention type: OTHER
Group type: OTHER
Intervention: Genetically modified potatoes
Description: Starch from genetically modified potatoes

Intervention type: OTHER
Group type: OTHER
Intervention: Genetically modified potatoes
Description: Starch from genetically modified potatoes

Intervention type: OTHER
Group type: OTHER
Intervention: Genetically modified potatoes
Description: Starch from genetically modified potatoes

Intervention type: OTHER
Group type: OTHER
Intervention: Genetically modified potatoes
Description: Starch from genetically modified potatoes
Study: NCT00408408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 600 mg/m2 IV
Study: NCT00953966

Intervention type: OTHER
Group type: OTHER
Intervention: Genetically modified potatoes
Description: Starch from genetically modified potatoes

Intervention type: OTHER
Group type: OTHER
Intervention: Genetically modified potatoes
Description: Starch from genetically modified potatoes
Study: NCT02647697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiprodil oral
Description: * Active Substance: Radiprodil~* Pharmaceutical Form: dry granules for oral suspension~* Concentration: 30 mg~* Route of Administration: oral use
Study: NCT03832205

Intervention type: DEVICE
Intervention: Capaciflector monitoring
Description: Non-invasive capaciflector monitoring of respiratory rate and heart rate.
Study: NCT03390803

Intervention type: OTHER
Intervention: effect of hemifacial spasm on intraocular pressure
Description: To evaluate the effect of Hemifacial spasm on Intraocular pressure measurement.
Study: NCT01525147

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YHB1411-2: level 1
Description: IV infusion
Study: NCT01526889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFG316
Description: LFG316 administered intravitreally (IVT)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Conventional Therapy administered in accordance with its prescribing info.
Study: NCT00408408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 600 mg/m2 IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 100 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 100 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 100 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 100 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 100 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 100 mg/m2 IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride (Adriamycin)
Description: 60 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride (Adriamycin)
Description: 60 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride (Adriamycin)
Description: 60 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride (Adriamycin)
Description: 60 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride (Adriamycin)
Description: 60 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride (Adriamycin)
Description: 60 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 1000 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 1000 mg/m2 IV
Study: NCT02718131

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: INFUSE Bone Graft (BMP-2)
Description: The INFUSE bone graft, containing BMP-2 on a collagen sponge, will be wrapped around the tibia during the surgical process.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: The control group will receive the standard surgical protocol, without addition of the INFUSE device.
Study: NCT01028859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-516 inj
Description: 5.0 mg/2ml; 1.0, 2.0, 3.3, 5, 7, 9 \~ mg/m2; Day 1, Day 8 every 3 weeks
Study: NCT02108158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azzalure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azzalure
Study: NCT04235959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT00608426

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive Outreach with choice of telephone or in-person smoking cessation services
Description: This group of participants is sent a recruitment letter, then receives a phone call to offer them their choice of smoking cessation services (either telephone care or in-person care).
Study: NCT01613209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Description: candesartan 16 mg tablets p. o. for 14 days (morning), then candesartan 32 mg tablets for 28 day (morning)s,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan/Amlodipin
Description: olmesartan/amlodipine 40/5 mg tablets for 14 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 28 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 42 days (evening)
Study: NCT02463812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT00706420

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Islet Transplantation + Immunosuppression
Description: Islet Transplantation + Immunosuppression (Sirolimus/Tacrolimus, daclizumab)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Islet cell transplantation
Description: Islet cell transplantation will occur through the portal vein.
Study: NCT03898297

Intervention type: RADIATION
Intervention: [18F]FPEB
Description: Radiotracer: \[18F\]FPEB

Intervention type: RADIATION
Intervention: [18F]FPEB
Description: Radiotracer: \[18F\]FPEB
Study: NCT01408459

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: No Motivational telephone Counseling
Study: NCT04085913

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Epinephrine
Description: Preincision injection, as is current practice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride-EPINEPHrine
Description: Preincision injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine
Description: Preincison injection of lidocaine and epinephrine and a postincision injection of Exparel
Study: NCT00601549

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Description: Laparoscopic surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional open surgery
Description: Open surgery
Study: NCT03898297

Intervention type: RADIATION
Intervention: [18F]FPEB
Description: Radiotracer: \[18F\]FPEB

Intervention type: RADIATION
Intervention: [11C]APP311
Description: Radiotracer: \[11C\]APP311, \[11C\]UCB-J

Intervention type: RADIATION
Intervention: [11C]APP311
Description: Radiotracer: \[11C\]APP311, \[11C\]UCB-J
Study: NCT03848741

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-Exercise Control
Description: Participants will not perform structured exercise and will continue with their normal physical activity for 12-weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training
Description: Participants will complete a 12-week whole-body progressive resistance exercise training program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise Training
Description: Participants will complete a 12-week whole-body progressive resistance exercise training program.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be given placebo capsules to consume for 12-weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will be given placebo capsules to consume for 12-weeks.
Study: NCT03898297

Intervention type: RADIATION
Intervention: [11C]APP311
Description: Radiotracer: \[11C\]APP311, \[11C\]UCB-J
Study: NCT00963742

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lenstec Softec HD IOL implantation
Description: surgical removal of cataract and implantation of Softec HD PCIOL
Study: NCT01298661

Intervention type: OTHER
Group type: OTHER
Intervention: Six-minute Step Test
Description: The patients underwent a test where they need to step up and down a 20cm test during six minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: Six-minute Step Test
Description: The patients underwent a test where they need to step up and down a 20cm test during six minutes.
Study: NCT01462396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CD34+ cells selected with the Miltenyi Clinimacs machine
Description: Haploidentical allogeneic stem cell transplant following sub-myeloablative conditioning and cell selection using the Miltenyi Clinimacs device
Study: NCT02147288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renasys*GO Negative Pressure Wound Therapy System
Description: Continuous, mechanical negative pressure wound therapy applied to drain in the immediate post-operative period (vs standard, closed-suction JP drains).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renasys*GO Negative Pressure Wound Therapy System
Description: Continuous, mechanical negative pressure wound therapy applied to drain in the immediate post-operative period (vs standard, closed-suction JP drains).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renasys*GO Negative Pressure Wound Therapy System
Description: Continuous, mechanical negative pressure wound therapy applied to drain in the immediate post-operative period (vs standard, closed-suction JP drains).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renasys*GO Negative Pressure Wound Therapy System
Description: Continuous, mechanical negative pressure wound therapy applied to drain in the immediate post-operative period (vs standard, closed-suction JP drains).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renasys*GO Negative Pressure Wound Therapy System
Description: Continuous, mechanical negative pressure wound therapy applied to drain in the immediate post-operative period (vs standard, closed-suction JP drains).
Study: NCT04201613

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic exoskeleton
Description: The Kinesiological Instrument for Normal and Altered Reaching Movements (KINARM) robotic exoskeleton used to provide therapy and assessment. The device has framework that supports the arms and the supports are adjustable to ensure a comfortable fit. Motors attached to the framework record shoulder and elbow movements and also move the arms.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic exoskeleton
Description: The Kinesiological Instrument for Normal and Altered Reaching Movements (KINARM) robotic exoskeleton used to provide therapy and assessment. The device has framework that supports the arms and the supports are adjustable to ensure a comfortable fit. Motors attached to the framework record shoulder and elbow movements and also move the arms.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic exoskeleton
Description: The Kinesiological Instrument for Normal and Altered Reaching Movements (KINARM) robotic exoskeleton used to provide therapy and assessment. The device has framework that supports the arms and the supports are adjustable to ensure a comfortable fit. Motors attached to the framework record shoulder and elbow movements and also move the arms.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic exoskeleton
Description: The Kinesiological Instrument for Normal and Altered Reaching Movements (KINARM) robotic exoskeleton used to provide therapy and assessment. The device has framework that supports the arms and the supports are adjustable to ensure a comfortable fit. Motors attached to the framework record shoulder and elbow movements and also move the arms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: This group will receive standard care with no additional therapy.
Study: NCT04600583

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon® Total Knee System (Stryker Orthopaedics, Mahwah, NJ USA)
Description: All patients, regardless of the alignment arm they are randomized to will undergo a primary total knee arthroplasty with the Triathlon® Total Knee System using Mako Robotic-Arm Assisted Technology. The surgical intervention will be administered by a physician wherein the expected duration of surgery is approximately 1.5 hours.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon® Total Knee System (Stryker Orthopaedics, Mahwah, NJ USA)
Description: All patients, regardless of the alignment arm they are randomized to will undergo a primary total knee arthroplasty with the Triathlon® Total Knee System using Mako Robotic-Arm Assisted Technology. The surgical intervention will be administered by a physician wherein the expected duration of surgery is approximately 1.5 hours.
Study: NCT03589027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel two rod sub-dermal implant
Description: Levonorgestrel (75 mg/rod), 2 rods (150 mg) inserted subdermally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel two rod sub-dermal implant
Description: Levonorgestrel (75 mg/rod), 2 rods (150 mg) inserted subdermally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: Oral ripilvirine 25mg once daily
Study: NCT02159664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: didgeridoo practice
Description: instrument lessons, 1X/w and daily practice, 20 min /d
Study: NCT02822469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy Treatment
Description: Treatment starts with 10 deep breathing movements for global relaxation. The anterior and posterior neck muscles, shoulder girdle and subdiaphragmatic will be addressed with myofascial techniques repeated 10 times in each stroke. The cervical spine will be pulled in the longitudinal direction. The draw will be held 1 time, lasting 1 minute. The thoracic region will receive mobilization technique in the anteroposterior direction,10 repeated movements involving all thoracic segment.~The treatment will be applied previously trained therapists, 4 weeks, 2 times a week, totaling eight sessions. The treatment time per session is about 25 minutes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ultrasound
Description: A detuned pulsed ultrasound will be applied to regions of the muscles around the shoulder girdle and anterior posterior cervical, for 25 minutes (2.5 minutes in each zone ). The device will be used with the internal cables disconnected for the placebo effect . However, you can handle it and adjust the doses and alarms as it is connected in order to simulate clinical practice and increase the credibility of the use of this device in the voluntary . The placebo treatment will be applied by previously trained therapists. Treatment will have 4 weeks, 2 times a week, totaling eight sessions.
Study: NCT01794052

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence based, DSS enabled, health care delivery model
Description: The study focus on preliminary work before a definitive randomised controlled trial. In this phase, we are developing an intervention for the evidence based management of hypertension and diabetes at primary care setting in India.~The components of the interventions that we are developing are:~1. A structured training of the health care staff for identifying people at risk of developing diabetes or hypertension~2. Treating patients as per a standard clinical guidelines~3. Giving health education to patients on lifestyle changes for better self-care~4. Optimizing the care pathways at the health facilities to enable better delivery of the intervention and~5. Development and implementation of a smartphone based decision support system (DSS) with inbuilt diagnostic and treatment algorithm
Study: NCT01440738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health workshops
Description: health workshops in relation to: Increase knowledge of healthy habits (physical activity, diet), incorporate and maintain a balanced diet. Incorporate and maintain regular physical activity
Study: NCT01050985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus and capecitabine
Description: temsirolimus in escalating doses starting at 15-mg IV on days 1 and 8 of a 14 day cycle capecitabine in escalating doses starting at 1000 mg/m2 by mouth twice a day on days 1-7 of a 14-day cycle
Study: NCT00696137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEMA Fentanyl
Description: buccal soluble film; 200, 400, 600, 800, and 1200 mcg fentanyl; up to 4 times daily
Study: NCT03589027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir+Ritonavir
Description: Oral DRV/r 600/100mg twice daily
Study: NCT03848741

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB+VitD
Description: Participants will be given HMB+VitD capsules to consume for 12-weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB+VitD
Description: Participants will be given HMB+VitD capsules to consume for 12-weeks
Study: NCT02269072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: Testosterone cream applied daily for two weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nesiritide
Description: Administered IV once during the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nesiritide
Description: Administered IV once during the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Leuprolide
Description: Administered twice during the study by injection
Study: NCT03981627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADO09 formulation
Description: Subcutaneous injection of ADO09 formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NovoRapid®
Description: Subcutaneous injection of insulin aspart
Study: NCT02990676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerised cognitive training
Description: Computerised cognitive training regime
Study: NCT04371601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Oseltamivir capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hormones
Description: a moderate amount of hormone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hormones
Description: a moderate amount of hormone

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: oxygen therapy
Description: oxygen therapy,mechanical ventilation and other supportive therapies

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oxygen therapy
Description: oxygen therapy,mechanical ventilation and other supportive therapies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: mesenchymal stem cells
Study: NCT00863291

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buprenorphine
Description: buprenorphine (range = 0.2-1.6 mg/day, starting dose = 0.2 mg/day, N = 20)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo in a manner similar to the active comparator
Study: NCT02922426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 3831
Description: Daily dosing for 21 consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Daily dosing for 21 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dosing for 21 consecutive days
Study: NCT00869518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rifabutin plus trimethoprim sulfamethoxazole
Description: rifabutin 300 mg PO daily or equivalent depending on concomitant medications plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo plus trimethoprim-sulfamethoxazole
Description: placebo plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days
Study: NCT01281033

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Thrombectomy
Description: In patients in the thrombus-aspiration group, this step is followed by the advancing of the 6-French Export Aspiration Catheter (Medtronic; crossing profile, 0.068 in.) into the target coronary segment during continuous aspiration.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AngioJet Rheolytic Thrombectomy (RT) System
Description: The AngioJet Rheolytic Thrombectomy (RT) System consists of a drive unit console, disposable pump set, and disposable catheter. Thrombectomy is accomplished by the introduction of a pressurized high velocity saline stream through directed orifices in the catheter distal tip so that thrombus is entrained (Bernoulli effect), dissociated into small particles, and evacuated from the body through the catheter and associated tubing. The pump set consists of a high pressure pulsatile pump which is used to generate the flow necessary for the dissociation and evacuation of thrombus, an effluent bag for the collection and storage of thrombus debris, and associated tubing.